Market
Will Lantheus launch a new Alzheimer's diagnostic product by 2025?
2
Resolution / Starting Odds
Yes, a new imaging agent • 25%
Yes, a new software or service • 25%
Yes, both an imaging agent and software/service • 25%
No new product/service • 25%
Official product announcements from Lantheus Holdings
Story
Lantheus Acquires Life Molecular Imaging for $350 Million, Potentially $400 Million, to Enhance Neuraceq Alzheimer's Diagnostics
Jan 13, 2025, 06:34 AM
Lantheus Holdings, a diagnostic imaging company based in the U.S., has announced its acquisition of Germany-based Life Molecular Imaging for an upfront payment of $350 million, with potential additional milestones of up to $400 million. This acquisition aims to enhance Lantheus's capabilities in the Alzheimer's disease radiodiagnostic market, particularly through Life Molecular Imaging's Neuraceq, an F-18 PET imaging agent approved for detecting beta-amyloid plaques in patients being evaluated for Alzheimer's. The transaction is part of Lantheus's strategy to accelerate innovation in the growing market for Alzheimer's diagnostics.
View original story
Similar markets
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
FDA • 25%
EMA • 25%
Both FDA and EMA • 25%
Neither • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
